Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GSK Re-submits Supplemental New Drug Application For Avodart
Reportedly, GSK had filed a supplemental new drug application (sNDA) for Avodart (dutasteride) with the FDA on 1 October, 2009. GSK said that the re-submission provides an update
Reportedly, GSK had filed a supplemental new drug application (sNDA) for Avodart (dutasteride) with the FDA on 1 October, 2009. GSK said that the re-submission provides an update
‘Multipacking’, in contrast to ‘case packing’, is the process, whether partially or entirely automated, by which a product is packed into a container that is then packed into
The study enrolled healthy volunteers 18 to 49 years in age who were immunized with a single injection of Novavax’s trivalent seasonal influenza VLP vaccine matched to the
Under terms of the agreement, Procaps will be responsible for obtaining regulatory and pricing approval in Colombia, South America. Procaps also will be responsible for the vial filling,
The MMRF has been awarded MannKind a $1m grant through its 2007 Biotech Investment Award program, a multi-year, results-driven commitment to fund the development of treatments for multiple
miRview mets test measures the expression levels of 48 microRNAs to identify 25 different primary origins. The test has been designed to assist patients and physicians diagnose cases
The complaint was regarding patent infringement under US patent No 7,682,612 based on GSK’s manufacture, marketing and sale of Arzerra in the US for the treatment of fludarabine
Discovered and developed by Eisai, Eritoran is believed to block activation of toll-like receptor 4 (TLR4). TLR4 is part of the innate immune system and, when it is
As per the agreement, the companies are expected to study short interfering RNA (siRNA) complexed to PTD-DRBD, with the ultimate goal of developing drugs using this technology. Hans
BioAlliance Pharma said that, with this approval to a total of 26 European countries for Loramyc and the recent Setofilm approval in 16 European countries, it is building